Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,380.33 -37.35 -0.26%
TOPIX 1,164.74 -1.81 -0.16%
HANG SENG 22,749.87 53.86 0.24%

Breaking New Ground -- Forest Laboratories, Inc. Expands to Canadian Market


Breaking New Ground -- Forest Laboratories, Inc. Expands to Canadian Market

Forest Laboratories Canada Inc. focused on bringing new treatment options to patients

TORONTO, Jan. 22, 2013 /CNW/ - Forest Laboratories, Inc. (NYSE: FRX) - an international pharmaceutical company - today announced its entry into the Canadian market through its wholly owned subsidiary Forest Laboratories Canada Inc. This development is in furtherance of Forest's plans to expand in global markets.

"We are excited about our venture in the Canadian marketplace," said Greg Engel, General Manager, Forest Laboratories Canada Inc. "We intend to introduce products that offer new treatment options that can address unmet medical needs and help improve patients' medical conditions. The company's goal is to bring important therapies to those Canadians who need them in compliance with Rx&D's Code of Ethical Practices. In the near-term, Forest Laboratories Canada Inc. is focused on bringing a number of therapeutic options to market in the areas of cardiology, respiratory medicine, gastroenterology, and mental health."

The Canadian head office is based in Toronto, Ontario, with a sales team that will reach from coast-to-coast.

About Forest Laboratories Canada Inc. & Forest Laboratories, Inc.

Forest Laboratories Canada Inc., the Canadian operation of Forest Laboratories, Inc. (NYSE: FRX), is dedicated to delivering innovative healthcare solutions across multiple therapeutic areas to patients with unmet medical needs. Forest Laboratories Canada Inc. is headquartered in Toronto, Ontario.  To learn more, visit www.frx.ca.

Forest Laboratories, Inc.'s longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest Laboratories, Inc.'s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. Forest Laboratories, Inc. is headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release may contain forward-looking statements within the meaning of United States securities laws. These statements may involve a number of risks and uncertainties, including the difficulty of predicting regulatory approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories, Inc.'s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent U.S. Securities and Exchange Commission filings. Neither Forest Laboratories Canada Inc. nor Forest Laboratories, Inc. assumes any obligation to update any forward-looking statements contained in this release to reflect new information or future events or developments.

Frank J. Murdolo VP Investor Relations Forest Laboratories, Inc. 212-224-6714 media.relations@frx.com

Jacqueline Zonneville NATIONAL Public Relations 416-848-1398 jzonneville@national.ca

SOURCE: Forest Laboratories Canada Inc.

To view this news release in HTML formatting, please use the following URL: http://www.newswire.ca/en/releases/archive/January2013/22/c7410.html

CO: Forest Laboratories Canada Inc. ST: Ontario

-0- Jan/22/2013 14:00 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement